Pyrimidine Sulfamide Derivatives for Selective ET A Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current endothelin receptor antagonists, particularly non-selective ET A/ET B dual antagonists, exhibit strong vasoconstrictor inhibition but also cause adverse effects, and there is a need for compounds with high selectivity and reduced hepatotoxicity.
Innovation Solution
Development of pyrimidine sulfamide derived compounds with a specific chemical structure that acts as highly selective ET A receptor antagonists, exhibiting a 10000-fold selectivity over ET B receptors and minimal induction of CYP3A expression and bile salt export pump inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Force
If non-selective ET A/ET B dual antagonists are used, then strong vasoconstrictor inhibition is achieved, but adverse effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (pyrimidine sulfamide derivatives) that selectively interact with ET A receptors over ET B receptors. The chemical structure includes specific substituents (R1-R6 groups) that create differential binding affinity, allowing the drug to exert strong vasoconstrictor inhibition through ET A receptors while minimizing activation of ET B receptors, thus reducing adverse effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the molecular structure (substituents at positions R1-R6, heteroatom types, chain lengths) to optimize the balance between ET A receptor affinity and ET B receptor affinity. This structural parameter optimization achieves high selectivity (10000-fold) while maintaining potent vasoconstrictor inhibition, thereby reducing adverse effects associated with non-selective dual antagonists.
2Reliability
If existing ET A receptor antagonists like macitentan are used, then ET A receptor antagonism is achieved, but hepatotoxicity risk increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of existing ET A receptor antagonists through systematic variation of substituents (R1-R6 groups including halogens, alkyl groups, heteroaryl groups) to alter pharmacokinetic properties and metabolic pathways. This structural optimization reduces induction of CYP3A and inhibition of bile salt export pump, thereby lowering hepatotoxicity risk while maintaining effective ET A receptor antagonism.
Solution Approach 2:
The patent employs copying by creating novel pyrimidine sulfamide derivative compounds that replicate the successful pharmacological activity of existing antagonists like macitentan but with improved safety profiles. The new compounds copy the essential ET A receptor binding motif while incorporating structural modifications that avoid the hepatotoxicity issues of prior art compounds.
3Object-affected harmful factors
If high selectivity for ET A receptors is achieved, then adverse effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a pyrimidine sulfamide core structure that provides ET A receptor binding activity, and variable substituent groups (R1-R6) that can be independently optimized for selectivity and pharmacokinetic properties. This modular segmentation allows systematic exploration of structure-activity relationships to achieve high selectivity while managing structural complexity through standardized building blocks.
Data Source
AI summary
Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.